SAN DIEGO--(BUSINESS WIRE)--Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Xiaohu Deng, Ph.D., has been appointed as head of technical operations and Lisa Percival has been appointed as head of regulatory.
“We are thrilled to welcome Xiaohu and Lisa to the growing Vividion team as we build the infrastructure necessary to support the advancement of our diversified pipeline of highly selective small molecule therapeutics for the treatment of cancers and immune disorders,” said Jeffrey Hatfield, chief executive officer of Vividion. “Their respective experiences across manufacturing and technical functions, and regulatory and business strategy, will be critical to Vividion’s success as we continue to leverage our chemoproteomic platform to identify our initial product candidates and progress through the development process.”
Xiaohu Deng, Ph.D., brings more than 20 years of experience in the biotechnology industry with a focus on drug product development and technical operations. Dr. Deng joins Vividion from Viracta Therapeutics, Inc. where he served as senior vice president, product development, leading the CMC function and IP strategy. Prior to that, he was a senior director, head of CMC at Kura Oncology, Inc. and Wellspring Biosciences, Inc., overseeing the CMC efforts on process R&D, manufacturing, compliance, regulatory and clinical supply for multiple programs through various phases of development. Earlier in his career, Dr. Deng held roles of increasing responsibility associated with chemistry R&D, CRO management and project management of discovery and preclinical development at Janssen Pharmaceutical Companies of Johnson & Johnson. Dr. Deng holds a Ph.D. in organic chemistry from Emory University, and an M.S. in physical chemistry and a B.S. in chemistry from Fudan University in Shanghai. Dr. Deng has more than 40 journal publications, a book chapter and holds 16 published patents.
Lisa Percival is a regulatory and clinical research professional who brings more than 25 years of experience to Vividion. She joins the company from Atlas Venture, where she has served as an entrepreneur in residence, regulatory strategy and as senior vice president, regulatory affairs for an Atlas stealth company. Prior to joining Atlas, Ms. Percival was vice president of regulatory affairs at Zafgen, Inc., where she was responsible for the development and execution of the global regulatory strategy for products to treat metabolic diseases and partnered with the executive team on business strategy. Before Zafgen, she worked for Bristol-Myers Squibb in clinical development and global regulatory strategy and policy, where she led the global pediatric center of excellence in support of all therapeutic areas and led global regulatory teams in virology, immunoscience and fibrosis to successful completion of clinical trials and IND, NDA, MAA and other global submissions and approvals. Ms. Percival holds an M.S. in physiology from the University of Connecticut and a B.S. in biology from Trinity College.
Vividion Therapeutics, Inc. is a biopharmaceutical company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a deep and diversified pipeline of highly selective small molecule therapeutics targeting high value disease-causing proteins in oncology and immunology. For more information, please visit www.vividion.com.